{"schema_version":"1","generated_at":"2026-10-28T10:03:32.975Z","data_as_of":null,"url":"https://www.findmykol.com/kol/gregory-behbehani","json_url":"https://www.findmykol.com/kol/gregory-behbehani/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"gregory-behbehani","name":"Gregory Behbehani","credential":"MD, PhD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"The Ohio State University Comprehensive Cancer Center","institution_url":"https://www.findmykol.com/institution/the-ohio-state-university","city":"Columbus","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1053679217","orcid":"0000-0002-9493-3607","openalex":"A5024815439"},"summary":"Gregory Behbehani is a Hematology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 198 publications with 3,225 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":198,"cited_by_count":3225,"h_index":26,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04049539","title":"Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction","phase":"PHASE1/PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Ohio State University Comprehensive Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT04049539","trial_url":"https://www.findmykol.com/trial/NCT04049539"}],"source":"trials"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":5,"shown":3,"withheld":2,"rows":[{"payer":"Adaptive Biotechnologies Corporation","program_year":2025,"amount_usd":1196.84,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1053679217"},{"payer":"JAZZ PHARMACEUTICALS INC.","program_year":2025,"amount_usd":123.69,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1053679217"},{"payer":"Adaptive Biotechnologies Corporation","program_year":2024,"amount_usd":1278.53,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1053679217"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1053679217","source":"payments"},"prescribing":{"data_year":2024,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":82.8,"classes_total":7,"classes":[{"class":"Isocitrate Dehydrogenase 2 Inhibitor","setting":"prescribed","share_pct":17.2,"drugs":[{"name":"Idhifa","share_pct":100}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":14,"drugs":[{"name":"Imatinib Mesylate","share_pct":53.8},{"name":"Bosulif","share_pct":46.2}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":9.7,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":9.7,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":7.5,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":7.5,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer","year":2025,"journal":"Cancer Immunology Research","source_url":"https://doi.org/10.1158/2326-6066.cir-24-0775","status":"verified"},{"title":"Results of a phase I trial with Haploidentical <scp>mbIL</scp>‐21 ex vivo expanded <scp>NK</scp> cells for patients with multiply relapsed and refractory <scp>AML</scp>","year":2024,"journal":"American Journal of Hematology","source_url":"https://doi.org/10.1002/ajh.27281","status":"verified"},{"title":"CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies","year":2024,"journal":"Blood Neoplasia","source_url":"https://doi.org/10.1016/j.bneo.2024.100032","status":"verified"},{"title":"Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment","year":2023,"journal":"Cell Reports","source_url":"https://doi.org/10.1016/j.celrep.2023.112891","status":"verified"},{"title":"Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia","year":2023,"journal":"Leukemia & lymphoma/Leukemia and lymphoma","source_url":"https://doi.org/10.1080/10428194.2023.2253480","status":"verified"}],"source":"works"},"contact":{"address_1":"460 W 10TH AVE","city":"Columbus","state":"OH","zip":"432101240","phone":"614-293-3196","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1053679217","source":"identity"},"similar":[{"name":"Gregory Otterson","slug":"gregory-otterson","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gregory-otterson","json_url":"https://www.findmykol.com/kol/gregory-otterson/profile.json"},{"name":"Raphael Pollock","slug":"raphael-pollock","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/raphael-pollock","json_url":"https://www.findmykol.com/kol/raphael-pollock/profile.json"},{"name":"Steven Clinton","slug":"steven-clinton","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/steven-clinton","json_url":"https://www.findmykol.com/kol/steven-clinton/profile.json"},{"name":"Claire Verschraegen","slug":"claire-verschraegen","institution":"The Ohio State University Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/claire-verschraegen","json_url":"https://www.findmykol.com/kol/claire-verschraegen/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":2,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-07-08","provider_certified":"2025-07-08","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}